SCHEMBL2436255

SCHEMBL2436255

CCOC(=O)CC(=O)Nc1cc(-c2nc3ccccc3nc2C)n[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.50
PKM P14618 1/20 0.49
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
KDM4E B2RXH2 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 2/20 0.38
TSHR P16473 2/20 0.38
PDE4B Q07343 1/20 0.38
PDE4D Q08499 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SAE1 Q9UBE0 1/20 0.37
UBA2 Q9UBT2 1/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435765 0.91 PKM (0.46) MAPK1PKMMAPK8MAPK9MAPK10
SCHEMBL2436439 0.91 PKM (0.46) MAPK1PKMMAPK8MAPK9MAPK10
SCHEMBL2441561 0.90 PKM (0.47) MAPK1PKMKDM4EALDH1A1HPGD
SCHEMBL2440253 0.89 MAPK1 (0.48) MAPK1PKMMAPK8MAPK9MAPK10
SCHEMBL2439066 0.89 PKM (0.45) MAPK1PKMMAPK8MAPK9MAPK10
SCHEMBL2439533 0.89 PKM (0.45) MAPK1PKMKDM4EALDH1A1HPGD
SCHEMBL2440866 0.89 PKM (0.45) MAPK1PKMKDM4ESMN1; SMN2ALDH1A1
SCHEMBL14120046 0.88 PKM (0.51) MAPK1PKMALDH1A1HPGDMEN1
SCHEMBL2440479 0.87 MAPK1 (0.48) MAPK1PKMMAPK8MAPK9MAPK10
SCHEMBL2436315 0.87 MAPK1 (0.46) MAPK1PKMMAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A MAPK1 286/4885PKM 296/4885MAPK8 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.